There are currently 1093 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Genomic Assessment of Patients With Severe Radiation Reactions
NCT03287349
Recruiting
Determine an underlying etiology behind unexpectedly severe reactions to radiation by blood draw.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/16/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Radiation; Reaction
Register for Updates
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)
NCT05399277
Recruiting
Transradial access (TRA) is the preferred vascular access site for invasive coronary angiography. TRA is limited by blockage of the radial artery post-procedurally, preventing future use of TRA. This is referred to as radial artery occlusion (RAO) and occurs in ~5% of cases. While intraprocedural anticoagulation has been studied extensively to mitigate this complication, oral anticoagulation post-TRA has not. The investigators will assess the impact of a one-week course of rivaroxaban post-TRA t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2023
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Radial Artery Occlusion
Register for Updates
A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy
NCT05590468
Recruiting
The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplement in adult-onset symptoms of mitochondrial myopathy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Mitochondrial Myopathy
Register for Updates
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
NCT04720976
Recruiting
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2023
Locations: Research Site, Rochester, Minnesota
Conditions: Solid Tumor, NSCLC
Register for Updates
The Oxford Risk Factors And Non-Invasive Imaging Study
NCT05169333
Recruiting
ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
05/09/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cardiovascular Diseases, Cardiovascular Risk Factors
Register for Updates
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
NCT04305444
Recruiting
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will determine the efficacy of the triple combination therapy, DTRM-555, in patients with R/R CLL or R/R non-Hodgkin's lymphoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Richter's Transformation
Register for Updates
KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models
NCT05338073
Recruiting
This study will assess the ability of the Known Medicine platform to predict the efficacy of certain cancer drug treatments and to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cancer, Predictive Cancer Model, Effects of Chemotherapy
Register for Updates
Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids
NCT05386615
Recruiting
The goal of this Registry Study is to capture clinical pregnancy outcomes and fibroid treatment background data for any subject post-Exablate treatment for their symptomatic fibroids.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
04/19/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Uterine Fibroid
Register for Updates
Screening for High Frequency Malignant Disease
NCT05117840
Recruiting
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/10/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Lung Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
NCT03574779
Recruiting
This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single arm) includes participants with recurrent ovarian cancer. Cohort B will not be initiated. Cohort C (randomized-2 arms) includes participants with newly diagnosed ovarian cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/09/2023
Locations: GSK Investigational Site, Rochester, Minnesota
Conditions: Ovarian Neoplasms
Register for Updates